Search

Your search keyword '"He, Jianming"' showing total 522 results
Start Over Author "He, Jianming"
522 results on '"He, Jianming"'

9. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.

Author

Perrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad, Kumar, Shaji, Bahlis, Nizar, Hulin, Cyrille, Orlowski, Robert, Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, He, Jianming, Ho, Kai, Van Rampelbergh, Rian, Uhlar, Clarissa, Wang, Jianping, Kobos, Rachel, Gries, Katharine, Fastenau, John, and Weisel, Katja

Subjects
Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Lenalidomide, Male, Middle Aged, Multiple Myeloma, Pain Measurement, Patient Reported Outcome Measures, Quality of Life, Time Factors, Treatment Outcome
Abstract

PURPOSE: To evaluate the effects of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) on patient-reported outcomes (PROs) in the phase III MAIA study. PATIENTS AND METHODS: PROs were assessed on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item and the EuroQol 5-dimensional descriptive system at baseline and every 3 months during treatment. By mixed-effects model, changes from baseline are presented as least squares means with 95% CIs. RESULTS: A total of 737 transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma were randomly assigned to D-Rd (n = 368) or Rd (n = 369). Compliance with PRO assessments was high at baseline (> 90%) through month 12 (> 78%) for both groups. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item global health status scores improved from baseline in both groups and were consistently greater with D-Rd at all time points. A global health status benefit was achieved with D-Rd, regardless of age (< 75 and ≥ 75 years), baseline Eastern Cooperative Oncology Group (ECOG) performance status score, or depth of response. D-Rd treatment resulted in significantly greater reduction in pain scores as early as cycle 3 (P = .0007 v Rd); the magnitude of change was sustained through cycle 12. Reductions in pain with D-Rd were clinically meaningful in patients regardless of age, ECOG status, or depth of response. Similarly, PRO improvements were observed with D-Rd and Rd on the EuroQol 5-dimensional descriptive system visual analog scale score. CONCLUSION: D-Rd compared with Rd was associated with faster and sustained clinically meaningful improvements in PROs, including pain, in transplant-ineligible patients with newly diagnosed multiple myeloma regardless of age, baseline ECOG status, or depth of treatment response.

Published
2021

23. A Liouville Theorem for a Class of Fractional Systems in $\mathbb{R}^n_+$

Author

Zhang, Lizhi, Yu, Mei, and He, Jianming

Subjects
Mathematics - Analysis of PDEs
Abstract

Let $0<\alpha,\beta<2$ be any real number. In this paper, we investigate the following semilinear system involving the fractional Laplacian \begin{equation*} \left\{\begin{array}{lll} (-\lap)^{\alpha/2} u(x)=f(v(x)), & (-\lap)^{\beta/2} v(x)=g(u(x)), & \qquad x\in\mathbb{R}^n_+, u,v\geq0, & \qquad x\in\mathbb{R}^n\setminus\mathbb{R}^n_+. \end{array}\right. \end{equation*} Applying a direct method of moving planes for the fractional Laplacian, without any decay assumption on the solutions at infinity, we prove Liouville theorems of nonnegative solutions under some natural conditions on $f$ and $g$.

Published
2016

31. Research on the Innovation of Industrial Economy Under the Background of Big Data

Author

Li, Xing, Yang, ZiHan, He, JianMing, Huo, Bingjie, Kacprzyk, Janusz, Series Editor, Pal, Nikhil R., Advisory Editor, Bello Perez, Rafael, Advisory Editor, Corchado, Emilio S., Advisory Editor, Hagras, Hani, Advisory Editor, Kóczy, László T., Advisory Editor, Kreinovich, Vladik, Advisory Editor, Lin, Chin-Teng, Advisory Editor, Lu, Jie, Advisory Editor, Melin, Patricia, Advisory Editor, Nedjah, Nadia, Advisory Editor, Nguyen, Ngoc Thanh, Advisory Editor, Wang, Jun, Advisory Editor, Abawajy, Jemal, editor, Choo, Kim-Kwang Raymond, editor, Islam, Rafiqul, editor, Xu, Zheng, editor, and Atiquzzaman, Mohammed, editor

Published
2019
Full Text
View/download PDF

34. Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study: Treatment pattern and outcomes in patients with multiple myeloma

Author

He, Jianming, Schmerold, Luke, Van Rampelbergh, Rian, Qiu, Lugui, Potluri, Ravi, Dasgupta, Anandaroop, Li, Lin, Li, Yunan, Hu, Peter, Nemat, Sepideh, Smugar, Steven S., Zeltzer, Paul, Appiani, Carlos, Li, Qing, Mehra, Maneesha, and Richarz, Ute

Published
2021
Full Text
View/download PDF

41. P-246 Real-world attrition rates after second-line therapy or later in patients from the flatiron database with relapsed/refractory multiple myeloma refractory to lenalidomide

Author

Dhakal, Binod, primary, Einsele, Hermann, additional, Schecter, Jordan, additional, Deraedt, William, additional, Lendvai, Nikoletta, additional, Slaughter, Ana, additional, Lonardi, Carolina, additional, Nair, Sandhya, additional, He, Jianming, additional, Kharat, Akshay, additional, Cost, Patricia, additional, Valluri, Satish, additional, and Fonseca, Rafael, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results